BioCentury | Jul 18, 2016
Company News

RedoxTherapies, Juno Therapeutics deal

...Juno acquired fellow cancer company RedoxTherapies. RedoxTherapies will receive $10 million in cash up front and...
...The company plans to study vipadenant in combination with its engineered T cells. In 2014, RedoxTherapies...
...to treat Parkinson’s disease, but Vernalis and Biogen discontinued its development based on toxicity concerns. RedoxTherapies...
BioCentury | Jul 14, 2016
Company News

Juno gets ADORA2A inhibitor in RedoxTherapies takeout

...Juno Therapeutics Inc. (NASDAQ:JUNO) acquired RedoxTherapies Inc. (Boston, Mass.) for $10 million in upfront cash and undisclosed...
...The company plans to study vipadenant in combination with its engineered T cells. In 2014, RedoxTherapies...
...to treat Parkinson's disease, but Vernalis and Biogen discontinued its development based on toxicity concerns. RedoxTherapies...
BioCentury | Oct 27, 2014
Company News

Vernalis, RedoxTherapeutics deal

...Vernalis granted RedoxTherapeutics exclusive, worldwide rights to develop and commercialize vipadenant ( V2006 ) for immuno-oncology...
...negative toxicity profile. The compound was in Phase II testing to treat Parkinson's disease (PD). RedoxTherapeutics...
...and commercial milestones, plus royalties (see BioCentury, July 19, 2010). Vernalis plc (LSE:VER), Winnersh, U.K. RedoxTherapeutics...
Items per page:
1 - 3 of 3
BioCentury | Jul 18, 2016
Company News

RedoxTherapies, Juno Therapeutics deal

...Juno acquired fellow cancer company RedoxTherapies. RedoxTherapies will receive $10 million in cash up front and...
...The company plans to study vipadenant in combination with its engineered T cells. In 2014, RedoxTherapies...
...to treat Parkinson’s disease, but Vernalis and Biogen discontinued its development based on toxicity concerns. RedoxTherapies...
BioCentury | Jul 14, 2016
Company News

Juno gets ADORA2A inhibitor in RedoxTherapies takeout

...Juno Therapeutics Inc. (NASDAQ:JUNO) acquired RedoxTherapies Inc. (Boston, Mass.) for $10 million in upfront cash and undisclosed...
...The company plans to study vipadenant in combination with its engineered T cells. In 2014, RedoxTherapies...
...to treat Parkinson's disease, but Vernalis and Biogen discontinued its development based on toxicity concerns. RedoxTherapies...
BioCentury | Oct 27, 2014
Company News

Vernalis, RedoxTherapeutics deal

...Vernalis granted RedoxTherapeutics exclusive, worldwide rights to develop and commercialize vipadenant ( V2006 ) for immuno-oncology...
...negative toxicity profile. The compound was in Phase II testing to treat Parkinson's disease (PD). RedoxTherapeutics...
...and commercial milestones, plus royalties (see BioCentury, July 19, 2010). Vernalis plc (LSE:VER), Winnersh, U.K. RedoxTherapeutics...
Items per page:
1 - 3 of 3